Tivic Health adjourns annual meeting to June 14; seeks more votes on reverse split and key proposals

Valion Bio, Inc.

Annual meeting on June 6, 2023 adjourned after only adjournment proposal approved; votes on director election, reverse split (1:5–1:30), and auditor ratification deferred to June 14.
Reverse stock split proposal authorizes Board to determine ratio within 12 months without further shareholder approval.
Record date remains April 13, 2023; shareholders urged to vote online at virtualshareholdermeeting.com/TIVC2023.
CEO needs additional votes for key measures; Board unanimously voted to reconvene on June 14 at 1:00 p.m. PT.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Valion Bio, Inc. shareholders approved Adjournment of the Annual Meeting to solicit additional proxies at the 2023-06-06 meeting.

Outcome: passed
Meeting: 2023-06-06

Exact text from the filing

The sole proposal presented to stockholders and voted on at the Annual Meeting on June 6, 2023 was the Adjournment Proposal, which was approved by the Company’s stockholders. The votes cast at the Annual Meeting with respect to the Adjournment Proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 14,272,410 897,725 53,791 -

View on SEC.gov

63 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Valion Bio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-027305

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.